Skymark Research Initiates Independent Research Coverage On PolyMedix, Inc.

CALGARY, Alberta, Nov. 12, 2009 (GLOBE NEWSWIRE) -- Skymark Research, a leading
provider of small- and micro-cap independent investment research, today
initiated coverage on PolyMedix, Inc. (OTCBB:PYMX). Skymark Research is
currently offering a complimentary trial subscription. To view our research go
to: www.skymarkresearch.com

About SMR:

Skymark Research is a leading provider of independent investment research in
North America. Our services include research analysis on the small- and
micro-cap markets, real-time news and financial data, market commentary and the
SMR newsletter. Skymark Research's staff of small-cap investment professionals
is dedicated to providing the small market's investment community with the tools
and avenues necessary to make the important investment decisions. To view our
research reports on a complimentary trial basis and take advantage of our other
services, go to www.skymarkresearch.com and click on the complimentary trial
subscription button on our home page, or go directly to our registration page at
www.skymarkresearch.com/signup.php

The Skymark Research logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6683

About PolyMedix, Inc. (OTCBB:PYMX)

PolyMedix is a publicly traded emerging biotechnology company focused on the
development of novel drugs and biomaterials for the treatment of infectious
diseases and acute cardiovascular disorders.

SMR Disclosure:

Skymarkresearch.com is not a registered investment advisor and nothing contained
in any materials should be construed as a recommendation to buy or sell any
securities. Skymark Research has not been compensated by any of the above
mentioned companies. Please read our report and visit our Web site,
www.skymarkresearch.com, for complete risks and disclosures.

-0-
CONTACT: Skymark Research
Dylan Boyle
202-657-6249
info@skymarkresearch.com